Xi Yu
No. 150, Haping Road, Nangang District
Harbin, 150081, China
Harbin, 150081, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Retraction Note: Repression of LncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis.
Journal: BMC cancer
Published: January 22, 2026
Integrated multi-omics analysis of single-cell and spatial transcriptomics reveals distinct hpv-associated immune microenvironment features and prognostic signatures in cervical cancer.
Journal: Frontiers in immunology
Published: April 25, 2025
Dosimetric and hematological toxicity analyses of bone marrow-sparing intensity-modulated radiation therapy for patients with cervical cancer treated with extended-field radiation therapy.
Journal: Precision radiation oncology
Published: October 04, 2024
Integrin β8 Facilitates Macrophage Infiltration and Polarization by Regulating CCL5 to Promote LUAD Progression.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: June 20, 2024
Bufalin: A promising therapeutic drug against the cisplatin-resistance of ovarian cancer by targeting the USP36/c-Myc axis.
Journal: Biochemical and biophysical research communications
Published: June 11, 2024
Omaveloxolone Prevents Polystyrene Microplastic-Induced Ovarian Granulosa Cell Apoptosis via the Keap1/Nrf2/HO-1 Pathway in Rats.
Journal: Molecular biotechnology
Published: January 20, 2024
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.
Journal: Molecular cancer
Published: January 13, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026